首页 | 本学科首页   官方微博 | 高级检索  
     

周络通胶囊对糖尿病周围神经病变小鼠坐骨神经糖基化终末产物及受体的影响
引用本文:张会欣,魏刚,王宏涛,朱慧明,崔庆飞,魏雄伟,高学东. 周络通胶囊对糖尿病周围神经病变小鼠坐骨神经糖基化终末产物及受体的影响[J]. 中国实验方剂学杂志, 2012, 18(23): 168-172
作者姓名:张会欣  魏刚  王宏涛  朱慧明  崔庆飞  魏雄伟  高学东
作者单位:1. 河北以岭医药研究院,河北省络病重点实验室,国家中医药管理局重点研究室,石家庄 050035
2. 石家庄以岭药业股份有限公司,石家庄,050035
基金项目:国家"十二五"重大新药创制科技重大专项(2011ZX09101-004-02);河北省中医药管理局科研计划项目(2011041)
摘    要:目的:观察周络通胶囊对糖尿病周围神经病变(DPN)小鼠的作用及对晚期糖基化终末产物(AGEs)及其受体的影响。方法:40只KK/Upj-Ay小鼠随机分为模型组、周络通胶囊高、中、低剂量组(6.85,3.43,1.71 g生药.kg-1),另设10只C57BL/6小鼠对照组。灌胃给药12周,观察一般情况,测定空腹血糖(FBG)及糖化血红蛋白(HbA1c);测定运动神经传导速度(MNCV);光镜及电镜观察坐骨神经形态学变化;荧光分光光度法测定坐骨神经中AGEs含量;荧光定量PCR和Western blot法测定坐骨神经AGEs受体(RAGE)表达。结果:周络通胶囊能不同程度改善模型小鼠症状,高剂量组能降低FBG和HbA1c(P<0.05,P<0.01);3组均能提高MNCV(P<0.05,P<0.01);减轻坐骨神经病理损伤;降低AGEs含量及RAGE mRNA和蛋白的表达(P<0.05,P<0.01)。结论:周络通胶囊对DPN有明显的改善作用,其机制可能与降低周围神经AGEs形成、抑制RAGE表达有关。

关 键 词:周络通胶囊  糖尿病周围神经病变  糖基化终末产物  糖基化终末产物受体
收稿时间:2012-05-23

Effects of Zhouluotong Capsule on Advanced Glycation End Products and its Receptor of Diabetic Peripheral Neuropathy in Mice
ZHANG Hui-xin,WEI Gang,WANG Hong-tao,ZHU Hui-ming,CUI Qing-fei,WEI Xiong-wei and GAO Xue-dong. Effects of Zhouluotong Capsule on Advanced Glycation End Products and its Receptor of Diabetic Peripheral Neuropathy in Mice[J]. China Journal of Experimental Traditional Medical Formulae, 2012, 18(23): 168-172
Authors:ZHANG Hui-xin  WEI Gang  WANG Hong-tao  ZHU Hui-ming  CUI Qing-fei  WEI Xiong-wei  GAO Xue-dong
Affiliation:Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Hebei Yiling Medicine Institute, Key Laboratory of State Administration of Traditional Chinese Medicine, Key Laboratory of Network Disease of Hebei Provinc, Shijiazhuang 050035, China;Shijiazhuang Yiling Pharmaceutical CO., LTD, Shijiazhuang 050035, China
Abstract:Objective: To investigate the effects of Zhouluotong capsule (ZLT) on diabetic peripheral neuropathy (DPN) and advanced glycation end products (AGEs) and its receptor in mice. Method: Fourty KK/Upj-Ay mice were randomly divided into model, ZLT (6.85,3.43,1.71 g·kg-1). Another ten C57BL/6 mice were as control group. Mice were given intragastrically for 12 weeks. The general appearance, fasting blood-glucose (FBG) and glycosylated hemoglobin (HbA1c) were observed. Motor nerve conduction velocity (MNCV) was observed. Pathological changes of sciatic nerve were observed by light microscope and electron microscope. The content of AGEs was examined by fluorospectrophotometry. The expression of AGEs receptor (RAGE) was examined by Real Time PCR and Western blot. Result: ZLT could ameliorate the symptom of model mice. High-dose ZLT could decrease FBG and HbA1c(P<0.05, P<0.01). MNCV were increased(P<0.05, P<0.01)and pathological lesions were alleviated in ZLT group. The content of AGE were significantly decreased(P<0.05, P<0.01). The expression of RAGE mRNA and protein were significantly decreased(P<0.05, P<0.01). Conclusion: ZLT has protective effects on DPN of mice via suppressing the expression of AGE,RAGE.
Keywords:Zhouluotong capsule  diabetic peripheral neuropathy  advanced glycation end products  advanced glycation end products receptor
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号